Abstract: The disclosure discloses a furan skeleton-containing iminoguanidine derivative, comprising 2,5-furan-bis(iminoguanidine) and acceptable salts of 2,5-furan-bis(iminoguanidine) as well as solvates thereof. The disclosure also discloses a preparation method of 2,5-furan-bis(iminoguanidine) and its use as an acidic gas absorbent and an anionic precipitant. The 2,5-furan-bis(iminoguanidine) of the disclosure can be conveniently regenerated and recycled alter absorbing acidic gases, is low in regeneration energy consumption and has reduced cost and improved efficiency. The 2,5-furan-bis(iminoguanidine) of the disclosure is simple in preparation, mild in reaction conditions, short in reaction time, high in yield and low in cost, and is easily prepared on large scale.

Abstract: A combined direct current circuit breaker includes a transfer branch, an energy absorption branch, at least two primary branches and at least two secondary branches; the transfer branch is connected in parallel with the energy absorption branch; the primary branches are in one-to-one correspondence with the second branches; the primary branches are connected with direct current outgoing lines of a direct current busbar in a high-voltage direct current power transmission system; the secondary branches are connected in series with the transfer branches and then connected in parallel with two ends of the primary branches corresponding to the secondary branches.

Abstract: The present invention provides a direct current circuit breaker and its implementation method, which includes a cutout circuit, a commutation circuit and a energy absorption circuit connected in parallel. Through using power semiconductor switch module to cut off the current, it will have a quickly action, without generating electric arc, while the modular construction also reduces the consistency requirements of the power electronic component.

Abstract: A Static Random Access Memory (SRAM) array power supply circuit is presented. The circuit comprises an SRAM test unit having a substantially same structure as a basic SRAM unit in the SRAM array; a switch device connected to a power source, the SRAM test unit, and the SRAM array; and a switch control circuit connected to the SRAM test unit and the switch device. When a test voltage in the SRAM test unit is lower than a threshold voltage, the switch device is closed so that the power source begins to charge the SRAM array and the SRAM test unit. The SRAM test unit provides an early warning for the SRAM array, allowing the latter to be charged upon fulfillment of a condition (e.g., charge is low). Compared to conventional circuits, this circuit provides an output voltage that is more stable and less susceptible to the changes in external conditions such as temperature or pressure.

Abstract: A Static Random Access Memory (SRAM) array power supply circuit is presented. The circuit comprises an SRAM test unit having a substantially same structure as a basic SRAM unit in the SRAM array; a switch device connected to a power source, the SRAM test unit, and the SRAM array; and a switch control circuit connected to the SRAM test unit and the switch device. When a test voltage in the SRAM test unit is lower than a threshold voltage, the switch device is closed so that the power source begins to charge the SRAM array and the SRAM test unit. The SRAM test unit provides an early warning for the SRAM array, allowing the latter to be charged upon fulfillment of a condition (e.g., charge is low). Compared to conventional circuits, this circuit provides an output voltage that is more stable and less susceptible to the changes in external conditions such as temperature or pressure.

Abstract: A combined direct current circuit breaker includes a transfer branch, an energy absorption branch, at least two primary branches and at least two secondary branches; the transfer branch is connected in parallel with the energy absorption branch; the primary branches are in one-to-one correspondence with the second branches; the primary branches are connected with direct current outgoing lines of a direct current busbar in a high-voltage direct current power transmission system; the secondary branches are connected in series with the transfer branches and then connected in parallel with two ends of the primary branches corresponding to the secondary branches.

Abstract: A compound for treating a disease, in particular cancer like non-small cell lung cancer, exceptionally inhibits activity of oncogenic ALK kinase. Compositions, particularly pharmaceutical compositions, are provided comprising this compound. Methods for targeting cancer cells harboring an abnormality in the ALK gene are also The compound for treating a disease has certain structural elements, namely a tricyclic, more specifically heterocyclic, backbone as the core part of the compound at least one highly electronegative atom in form of a tertiary amine attached to the backbone via an at most 6-membered linking group with a terminal highly electronegative atom in form of a nitrogen as secondary amine, and a further hydrophobic moiety fused to the backbone. The structural components allow for an advantageous interaction with the ALK kinase domain. The compound therefor represents a highly promising treatment option for patients in particular those bearing ALK-dependent non-small cell lung cancer.

Abstract: The administration of a compound advantageously efficacious as ROS1 inhibitor and its effect on subjects with cancer includes administering a compound having certain structural components such as a quinoline moiety in the backbone and at least one tertiary amine containing moiety in a side chain as well as heteroatoms, in particular oxygen atoms, present in the backbone and the side chain for treating a subject suffering from a disease such as cancer. The presence of such structural components allows for an advantageous interaction with the ROS1 kinase domain, in particular with the hinge region. The administered compounds represent a highly promising opportunity in particular for patients bearing ROS1-dependent cancer. A method for targeting tumor cells harboring an abnormality in ROS1 gene includes contacting a cell with compounds of the present invention as well as pharmaceutical compositions comprising such compounds.

Abstract: A compound for treating a disease, in particular cancer like non-small cell lung cancer, exceptionally inhibits activity of oncogenic ALK kinase. Compositions, particularly pharmaceutical compositions, are provided comprising this compound. Methods for targeting cancer cells harboring an abnormality in the ALK gene are also The compound for treating a disease has certain structural elements, namely a tricyclic, more specifically heterocyclic, backbone as the core part of the compound at least one highly electronegative atom in form of a tertiary amine attached to the backbone via an at most 6-membered linking group with a terminal highly electronegative atom in form of a nitrogen as secondary amine, and a further hydrophobic moiety fused to the backbone. The structural components allow for an advantageous interaction with the ALK kinase domain. The compound therefor represents a highly promising treatment option for patients in particular those bearing ALK-dependent non-small cell lung cancer.

Abstract: The present invention provides methods for treatment of a RAS-positive disease, in particular KRAS-positive non-small cell lung cancer as well as a method for potentiating the apoptotic activity of a PDE? inhibitor by combining the PDE? inhibitor with a direct autophagy inhibitor. The PDE? inhibitor is preferably, but not exclusively, deltarasin, and the direct autophagy inhibitor is in particular 3-methyladenine. Further provided by the present invention are a kit and a pharmaceutical composition comprising the PDE? inhibitor and a direct autophagy inhibitor. The methods of the present invention in particular provide a new treatment option for RAS-positive diseases such as KRAS-positive non-small cell lung cancer allowing for an increased apoptotic activity of the PDE? inhibitor by simultaneously blocking its “tumor protective” autophagy.

Abstract: A compound suitable for treating cancer, in particular NSCLC, inhibits activity of oncogenic ROS1 kinase and ALK kinase. The compound has certain structural components such as a quinoline moiety in the backbone and at least one phenyl-containing moiety in a side chain with a hydrophobic substituent attached to the backbone via an up to 6-membered linking group as well as a further hydrophobic moiety. The presence of the structural components allows for an advantageous interaction with the ROS1 kinase domain and, further, with the ALK kinase domain. Hence, said compound represents a highly promising opportunity for patients bearing ROS1- or ALK-dependent cancer. A composition, in particular a pharmaceutical composition, includes the compound. A method for targeting cancer cells harboring an abnormality in ROS1 gene or ALK gene includes contacting a cell with the compound.

Abstract: The present invention relates to the administration of a novel compound advantageously efficacious as PDE? inhibitor and its effects on subjects with cancer. More specifically, the present invention is directed to a method for administering a compound having favorable geometric properties for interacting with the PDE? prenyl-binding pocket, namely has certain structural components such as a three-cyclic backbone and at least one benzoyl-moiety in a side chain having at least two substituents containing highly electronegative atoms and being linked to the backbone via an aliphatic chain, for treating a subject suffering from a disease such as cancer, in particular non-small-cell lung cancer. The presence of said structural components particularly contributes to an advantageous interaction with PDE?, in particular with amino acids deep in the binding pocket.

Abstract: The administration of a compound advantageously efficacious as ROS1 inhibitor and its effect on subjects with cancer includes administering a compound having certain structural components such as a quinoline moiety in the backbone and at least one tertiary amine containing moiety in a side chain as well as heteroatoms, in particular oxygen atoms, present in the backbone and the side chain for treating a subject suffering from a disease such as cancer. The presence of such structural components allows for an advantageous interaction with the ROS1 kinase domain, in particular with the hinge region. The administered compounds represent a highly promising opportunity in particular for patients bearing ROS1-dependent cancer. A method for targeting tumor cells harboring an abnormality in ROS1 gene includes contacting a cell with compounds of the present invention as well as pharmaceutical compositions comprising such compounds.

Abstract: The present invention provides a compound that inhibits activity of oncogenic ROS1, a composition comprising said compound. The present invention also provides the use of said composition for treating cancer.

Abstract: The present invention provides a compound that inhibits activity of oncogenic ROS1, a composition comprising said compound. The present invention also provides the use of said composition for treating cancer.

Abstract: A compound suitable for treating cancer, in particular NSCLC, inhibits activity of oncogenic ROS1 kinase and ALK kinase. The compound has certain structural components such as a quinoline moiety in the backbone and at least one phenyl-containing moiety in a side chain with a hydrophobic substituent attached to the backbone via an up to 6-membered linking group as well as a further hydrophobic moiety. The presence of the structural components allows for an advantageous interaction with the ROS1 kinase domain and, further, with the ALK kinase domain. Hence, said compound represents a highly promising opportunity for patients bearing ROS1- or ALK-dependent cancer. A composition, in particular a pharmaceutical composition, includes the compound. A method for targeting cancer cells harboring an abnormality in ROS1 gene or ALK gene includes contacting a cell with the compound.

Abstract: The present invention discloses that a method of treating cancer, preferably non-small cell lung cancer, comprises administrating mitoxantrone. The present invention also discloses a method of inhibiting ROS1 kinase comprising administrating mitoxantrone. A pharmaceutical composition comprising mitoxantrone is also disclosed.

Abstract: A method for manufacturing carbon nanotubes is provided. First, a substrate having a first surface and a second surface opposite to the first surface is provided. Second, a catalyst film is formed on the first surface of the substrate, wherein the catalyst film comprises a carbonaceous material. Third, a mixture of a carrier gas and a carbon source gas is flew across the catalyst film. Forth, a focused laser beam is irradiated on the substrate to grow a carbon nanotube array from the substrate.

Abstract: The present invention relates to the technical field of communications, and provides an app icon processing method and a communication terminal. The processing method comprises the steps of: determining whether or not an existing application is supported by the current operating environment, the current operating environment comprising the current network environment and/or the current terminal environment, etc.; then, inactivating the app icon corresponding to the existing application not supported by the current operating environment, or, downloading and displaying an application supported by the current operating environment. Preferably, the inactivated app icon is removed or displayed in an inactive state. In this way, in the present invention, the app icons of a plurality of inactive applications can be hidden on the communication terminal so that app icons are cleared automatically, thus aiding the user to find quickly the needed and active app icons.